JP2009531036A - Ｖｅｇｆ受容体融合タンパク質およびそれらの使用 - Google Patents
Ｖｅｇｆ受容体融合タンパク質およびそれらの使用 Download PDFInfo
- Publication number
- JP2009531036A JP2009531036A JP2009501824A JP2009501824A JP2009531036A JP 2009531036 A JP2009531036 A JP 2009531036A JP 2009501824 A JP2009501824 A JP 2009501824A JP 2009501824 A JP2009501824 A JP 2009501824A JP 2009531036 A JP2009531036 A JP 2009531036A
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- angiogenesis
- domain
- kdr
- vegf receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 100
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 100
- 108091008605 VEGF receptors Proteins 0.000 title claims description 17
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 title claims description 17
- 230000033115 angiogenesis Effects 0.000 claims abstract description 33
- 238000011282 treatment Methods 0.000 claims abstract description 27
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 15
- 206010012689 Diabetic retinopathy Diseases 0.000 claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 claims abstract description 13
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 claims abstract description 13
- 208000030533 eye disease Diseases 0.000 claims abstract description 9
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 21
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 18
- 230000002207 retinal effect Effects 0.000 claims description 15
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims description 14
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 13
- 208000001344 Macular Edema Diseases 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 8
- 208000022873 Ocular disease Diseases 0.000 claims description 8
- 201000011190 diabetic macular edema Diseases 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 238000002054 transplantation Methods 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 230000015271 coagulation Effects 0.000 claims description 6
- 238000005345 coagulation Methods 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 206010058202 Cystoid macular oedema Diseases 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 206010038903 Retinal vascular occlusion Diseases 0.000 claims description 5
- 230000003321 amplification Effects 0.000 claims description 5
- 201000010206 cystoid macular edema Diseases 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 5
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 5
- 108091008146 restriction endonucleases Proteins 0.000 claims description 5
- 238000010276 construction Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 206010066901 Treatment failure Diseases 0.000 claims description 3
- 230000002159 abnormal effect Effects 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 238000001976 enzyme digestion Methods 0.000 claims description 3
- 230000004927 fusion Effects 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 108020003175 receptors Proteins 0.000 abstract description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 2
- 208000002780 macular degeneration Diseases 0.000 description 16
- 230000004304 visual acuity Effects 0.000 description 14
- 238000009472 formulation Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 210000001525 retina Anatomy 0.000 description 12
- 230000007423 decrease Effects 0.000 description 11
- 210000000416 exudates and transudate Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 10
- 210000001508 eye Anatomy 0.000 description 10
- 230000000649 photocoagulation Effects 0.000 description 10
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 9
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 208000009857 Microaneurysm Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 230000036961 partial effect Effects 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 208000032843 Hemorrhage Diseases 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- 238000002583 angiography Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 206010003694 Atrophy Diseases 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 230000037444 atrophy Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000012537 formulation buffer Substances 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 201000004569 Blindness Diseases 0.000 description 5
- 206010025415 Macular oedema Diseases 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 5
- 229910052782 aluminium Inorganic materials 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 201000010230 macular retinal edema Diseases 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 229940068977 polysorbate 20 Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000034158 bleeding Diseases 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 238000013532 laser treatment Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- -1 tromeramol Substances 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- 206010002329 Aneurysm Diseases 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000002491 angiogenic effect Effects 0.000 description 3
- 229920005549 butyl rubber Polymers 0.000 description 3
- 210000003161 choroid Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 208000004644 retinal vein occlusion Diseases 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000011146 sterile filtration Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229940074410 trehalose Drugs 0.000 description 3
- 239000002525 vasculotropin inhibitor Substances 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 239000003390 Chinese drug Substances 0.000 description 2
- 101150088608 Kdr gene Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 2
- 206010064145 Retinal aneurysm Diseases 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001772 anti-angiogenic effect Effects 0.000 description 2
- 229940120638 avastin Drugs 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000004263 retinal angiogenesis Effects 0.000 description 2
- 208000032253 retinal ischemia Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229940074404 sodium succinate Drugs 0.000 description 2
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940074409 trehalose dihydrate Drugs 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 208000007135 Retinal Neovascularization Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
- 201000005667 central retinal vein occlusion Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000012633 leachable Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940076783 lucentis Drugs 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940005014 pegaptanib sodium Drugs 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 210000001210 retinal vessel Anatomy 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- SRWFBFUYENBCGF-UHFFFAOYSA-M sodium;chloride;hydrochloride Chemical compound [Na+].Cl.[Cl-] SRWFBFUYENBCGF-UHFFFAOYSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000008354 tissue degradation Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100662572A CN100502945C (zh) | 2006-03-31 | 2006-03-31 | Vegf受体融合蛋白在治疗眼睛疾病中的应用 |
| PCT/CN2007/001021 WO2007112675A1 (fr) | 2006-03-31 | 2007-03-29 | Protéine de fusion du récepteur du vegf et son utilisation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009531036A true JP2009531036A (ja) | 2009-09-03 |
| JP2009531036A5 JP2009531036A5 (enExample) | 2009-12-17 |
Family
ID=37736587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009501824A Pending JP2009531036A (ja) | 2006-03-31 | 2007-03-29 | Ｖｅｇｆ受容体融合タンパク質およびそれらの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20090264358A1 (enExample) |
| EP (1) | EP2000483A4 (enExample) |
| JP (1) | JP2009531036A (enExample) |
| KR (1) | KR20090010030A (enExample) |
| CN (1) | CN100502945C (enExample) |
| AU (1) | AU2007234272A1 (enExample) |
| BR (1) | BRPI0710223A2 (enExample) |
| CA (1) | CA2647142A1 (enExample) |
| RU (1) | RU2008136655A (enExample) |
| WO (1) | WO2007112675A1 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013516169A (ja) * | 2009-12-31 | 2013-05-13 | インダストリー−ユニバーシティー コーポレーション ファウンデーション ハンヤン ユニバーシティー | 抗血管新生活性を有する組換えアデノウイルス |
| JP2016037488A (ja) * | 2014-08-11 | 2016-03-22 | 日本化薬株式会社 | ＴＧＦβ阻害機能を持つキメラタンパク質 |
| JP2021534825A (ja) * | 2018-12-07 | 2021-12-16 | 榮昌生物制薬(烟台)股▲フン▼有限公司Remegen Co., Ltd. | 二機能血管新生阻害剤及びその用途 |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2586459T (lt) | 2005-03-25 | 2017-09-25 | Regeneron Pharmaceuticals, Inc. | Vegf antagonisto kompozicijos |
| CN104434770A (zh) | 2006-06-16 | 2015-03-25 | 瑞泽恩制药公司 | 适合玻璃体内施用的vegf拮抗剂的制剂 |
| CN101279092B (zh) * | 2007-04-02 | 2010-10-27 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在制备治疗与血管生成有关的疾病中的应用 |
| CN101721699B (zh) * | 2008-10-13 | 2012-11-07 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在制备治疗伴随vegf升高的炎症反应的药物中的应用 |
| CN102233132B (zh) * | 2010-04-28 | 2013-10-23 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在制备抑制眼表新生血管生长的药物中的应用 |
| CN102380096B (zh) * | 2010-08-31 | 2014-04-30 | 成都康弘生物科技有限公司 | 一种含有抑制血管增生的融合蛋白的药物组合物及用途 |
| CN103816115B (zh) * | 2010-08-31 | 2017-06-27 | 成都康弘生物科技有限公司 | 一种含有抑制血管增生的融合蛋白的药物组合物及用途 |
| JP2014503555A (ja) | 2011-01-13 | 2014-02-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 |
| KR102049990B1 (ko) | 2013-03-28 | 2019-12-03 | 삼성전자주식회사 | c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| EP3985023A1 (en) | 2014-12-11 | 2022-04-20 | Bayer Healthcare LLC | Treatment of age related macular degeneration with a small active choroidal neovascularization lesion |
| WO2017046140A1 (en) | 2015-09-18 | 2017-03-23 | Bayer Pharma Aktiengesellschaft | Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia |
| ES2927049T3 (es) | 2017-11-30 | 2022-11-02 | Regeneron Pharma | Uso de un antagonista del VEGF para tratar trastornos oculares angiogénicos |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| PT4364724T (pt) | 2018-05-10 | 2025-12-16 | Regeneron Pharma | Formulações contendo uma proteína de fusão do recetor do vegf de concentração elevada |
| CN115335529A (zh) * | 2019-11-26 | 2022-11-11 | 马萨诸塞大学 | 用于递送kh902(康柏西普)的重组腺相关病毒及其用途 |
| EP3906303A1 (en) | 2019-12-06 | 2021-11-10 | Regeneron Pharmaceuticals, Inc. | Anti-vegf protein compositions and methods for producing the same |
| CA3182893A1 (en) | 2020-05-08 | 2021-11-11 | Regeneron Pharmaceuticals, Inc. | Vegf traps and mini-traps and methods for treating ocular disorders and cancer |
| ES3041647T3 (en) | 2021-05-17 | 2025-11-13 | Regeneron Pharma | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders |
| IL315347A (en) | 2022-03-15 | 2024-11-01 | Regeneron Pharma | Prolonged high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders |
| CN119136823A (zh) | 2022-03-15 | 2024-12-13 | 瑞泽恩制药公司 | 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案 |
| KR20250065646A (ko) | 2022-09-16 | 2025-05-13 | 치루 파머수티컬 컴퍼니 리미티드 | 안정적인 고농도 자가완충식 약물 조성물 |
| WO2024263995A1 (en) | 2023-06-23 | 2024-12-26 | Regeneron Pharmaceuticals, Inc. | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders |
| WO2025140553A1 (zh) * | 2023-12-27 | 2025-07-03 | 成都康弘生物科技有限公司 | 一种含有抗vegf的融合蛋白的药物组合物 |
| WO2025217334A1 (en) | 2024-04-09 | 2025-10-16 | Regeneron Pharmaceuticals, Inc. | Low concentration vegf receptor fusion protein containing formulations |
| CN118108862B (zh) * | 2024-04-29 | 2024-08-09 | 上海鼎新基因科技有限公司 | 抗血管新生的融合蛋白及其应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005000895A2 (en) * | 2003-06-30 | 2005-01-06 | Regeneron Pharmaceuticals, Inc. | Vegf traps and therapeutic uses thereof |
| CN1706867A (zh) * | 2004-06-08 | 2005-12-14 | 成都康弘科技实业（集团）有限公司 | 抑制血管新生的融合蛋白质及其用途 |
| WO2005121176A1 (en) * | 2004-06-08 | 2005-12-22 | Chengdu Kanghong Biotechnologies Co. Ltd | Angiogenesis-inhibiting chimeric protein and the use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100523187C (zh) * | 1999-06-08 | 2009-08-05 | 里珍纳龙药品有限公司 | 具有改善的药物动力学特性的修饰嵌合多肽 |
| AU2004273619A1 (en) * | 2003-09-23 | 2005-03-31 | Novartis Ag | Combinations of a VEGF receptor inhibitor with other therapeutic agents |
-
2006
- 2006-03-31 CN CNB2006100662572A patent/CN100502945C/zh active Active
-
2007
- 2007-03-29 EP EP07720595A patent/EP2000483A4/en not_active Withdrawn
- 2007-03-29 KR KR1020087025464A patent/KR20090010030A/ko not_active Withdrawn
- 2007-03-29 CA CA002647142A patent/CA2647142A1/en not_active Abandoned
- 2007-03-29 BR BRPI0710223-2A patent/BRPI0710223A2/pt not_active IP Right Cessation
- 2007-03-29 WO PCT/CN2007/001021 patent/WO2007112675A1/zh not_active Ceased
- 2007-03-29 AU AU2007234272A patent/AU2007234272A1/en not_active Abandoned
- 2007-03-29 RU RU2008136655/13A patent/RU2008136655A/ru not_active Application Discontinuation
- 2007-03-29 JP JP2009501824A patent/JP2009531036A/ja active Pending
-
2008
- 2008-09-29 US US12/241,017 patent/US20090264358A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005000895A2 (en) * | 2003-06-30 | 2005-01-06 | Regeneron Pharmaceuticals, Inc. | Vegf traps and therapeutic uses thereof |
| CN1706867A (zh) * | 2004-06-08 | 2005-12-14 | 成都康弘科技实业（集团）有限公司 | 抑制血管新生的融合蛋白质及其用途 |
| WO2005121176A1 (en) * | 2004-06-08 | 2005-12-22 | Chengdu Kanghong Biotechnologies Co. Ltd | Angiogenesis-inhibiting chimeric protein and the use |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013516169A (ja) * | 2009-12-31 | 2013-05-13 | インダストリー−ユニバーシティー コーポレーション ファウンデーション ハンヤン ユニバーシティー | 抗血管新生活性を有する組換えアデノウイルス |
| JP2016037488A (ja) * | 2014-08-11 | 2016-03-22 | 日本化薬株式会社 | ＴＧＦβ阻害機能を持つキメラタンパク質 |
| JP2021534825A (ja) * | 2018-12-07 | 2021-12-16 | 榮昌生物制薬(烟台)股▲フン▼有限公司Remegen Co., Ltd. | 二機能血管新生阻害剤及びその用途 |
| JP2023052623A (ja) * | 2018-12-07 | 2023-04-11 | 榮昌生物制薬（烟台）股▲フン▼有限公司 | 二機能血管新生阻害剤及びその用途 |
| JP7516381B2 (ja) | 2018-12-07 | 2024-07-16 | 榮昌生物制薬（烟台）股▲フン▼有限公司 | 二機能血管新生阻害剤及びその用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007112675A1 (fr) | 2007-10-11 |
| CN1915427A (zh) | 2007-02-21 |
| CN100502945C (zh) | 2009-06-24 |
| WO2007112675A8 (fr) | 2009-07-09 |
| US20090264358A1 (en) | 2009-10-22 |
| BRPI0710223A2 (pt) | 2011-08-02 |
| CA2647142A1 (en) | 2007-10-11 |
| AU2007234272A1 (en) | 2007-10-11 |
| RU2008136655A (ru) | 2010-05-10 |
| EP2000483A2 (en) | 2008-12-10 |
| EP2000483A9 (en) | 2009-03-18 |
| KR20090010030A (ko) | 2009-01-28 |
| EP2000483A4 (en) | 2009-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009531036A (ja) | Ｖｅｇｆ受容体融合タンパク質およびそれらの使用 | |
| CN116585466A (zh) | 含有高浓度vegf受体融合蛋白的制剂 | |
| JPH11222441A (ja) | ヒト成長ホルモン含有水性医薬組成物 | |
| CN100567325C (zh) | Vegf受体融合蛋白及其在制备治疗眼睛疾病的药物中的应用 | |
| US11944663B2 (en) | Method for treating angiogenic eye disorders using VEGF antagonists | |
| JP2020523307A (ja) | 血管新生緑内障を治療するための非抗体ｖｅｇｆアンタゴニスト | |
| US20240299564A1 (en) | Peptide carriers and delivery to the eye of a subject | |
| CN100484957C (zh) | 胸腺素β4衍生物及其应用 | |
| JP2025500123A (ja) | ギャップ結合モジュレーターおよび加齢黄斑変性の処置のためのその使用 | |
| TWI732372B (zh) | 一種雙功能血管生成抑制劑及其用途 | |
| TWI737972B (zh) | 心肌再灌流的方法及套组與減緩或減少心肌再灌流損傷的方法 | |
| US20220133866A1 (en) | Method for the Treatment of a Disease Using Pigment Epithelium-Derived Factor (PEDF) | |
| EP4429693B1 (en) | Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion | |
| EP3964227A1 (en) | Method for the treatment of a disease using pigment epithelium-derived factor (pedf) | |
| HK40115628A (en) | Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion | |
| HK40115628B (en) | Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion | |
| WO2024236190A1 (en) | Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion | |
| IL301042A (en) | Pigment epithelium-derived factor (pedf) for use in treatment of macular degeneration or choroidal neovascularisation | |
| CN116601299A (zh) | 用于脉络膜上施用的制剂诸如具有聚集体形成的制剂 | |
| CN116635004A (zh) | 用于脉络膜上施用的制剂如凝胶制剂 | |
| CA3253955A1 (en) | ANNEXIN A5 MONOMER FOR USE IN THE TREATMENT OF MACULAR EDEMA OR RETINAL VEIN OCCUSION | |
| TW201345545A (zh) | 一種用以治療眼部脈絡膜血管新生之醫藥組合物 | |
| EP4003353A1 (en) | Bromocriptine for use in treating eye diseases associated with elevated level of vegf and a pharmaceutical composition comprising bromocriptine | |
| HK40052983A (en) | High concentration vegf receptor fusion protein containing formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091026 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091026 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120515 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121016 |